Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Analysis  > 2026  > Accepted Manu
Yixin Liu, Jianfeng Zhou, Zhipeng Gong, Yanru Feng, Xiang Li, Qixin Shang, Yangping Wu, Yushang Yang. Mapping the global research landscape of nanomaterial-based cancer vaccines: A comprehensive bibliometric and visualized review[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2026.101612
Citation: Yixin Liu, Jianfeng Zhou, Zhipeng Gong, Yanru Feng, Xiang Li, Qixin Shang, Yangping Wu, Yushang Yang. Mapping the global research landscape of nanomaterial-based cancer vaccines: A comprehensive bibliometric and visualized review[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2026.101612
shu

Mapping the global research landscape of nanomaterial-based cancer vaccines: A comprehensive bibliometric and visualized review

doi: 10.1016/j.jpha.2026.101612

  • a. Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, 610041, China;

  • b. Department of Thoracic Surgery and Institute of Thoracic Oncology, West China Hospital, Frontiers Science Center for Disease-related Molecular Network Sichuan University, Chengdu, 610097, China;

  • c. Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, 610041, China

Funds:

We thank Dr. Shenglu Lian from West China School of Clinical Medicine, Sichuan University, for his professional support in figure reconstruction and resolution optimization. This work was supported by funds from Scientific Research and Talent Cultivation Fund of Guizhou Moutai Hospital (Grant No.: MTyk-2022-03), the Science and Technology Cooperation Special Fund of Sichuan University-Zigong (Grant No.: 2021CDZG-24) and Basic Research Projects of Qinghai Provincial Department of Science and Technology (Grant No.: 2023-ZJ-791).

  • Received Date: Jul. 24, 2025
  • Accepted Date: Mar. 23, 2026
  • Rev Recd Date: Feb. 23, 2026
  • Available Online: Mar. 28, 2026
    Abstract
  • Nanomaterial-based cancer vaccines constitute a rapidly evolving frontier in cancer immunotherapy, offering innovative solutions to overcome the inherent limitations of conventional vaccine platforms, including suboptimal antigen delivery, poor immunogenicity, and systemic toxicity. With the advancement of nanotechnology, various nanocarriers—such as lipid nanoparticles, polymeric systems, and inorganic materials—have been engineered to enhance antigen stability, facilitate targeted delivery, and potentiate antitumor immune responses. In this review, we systematically examine the global research trends and scientific progression in the field of nanomaterial-based cancer vaccines from 2000 to 2024, based on bibliometric analysis of publications indexed in the Web of Science Core Collection. Analytical tools including CiteSpace, HistCite, and Alluvial Generator were employed to visualize co-citation networks, identify high-impact research clusters, detect emerging topics through keyword bursts, and delineate collaborative dynamics. A total of 3,910 publications were analyzed, revealing an exponential increase in research output since 2015, with a notable emphasis on lipid nanoparticle based mRNA vaccines and combinatorial immunotherapeutic approaches in recent years. This review provides a comprehensive synthesis of the current intellectual structure, thematic evolution, and collaboration landscape of nanomaterial-based cancer vaccine research, offering valuable perspectives to guide future investigations, foster global research synergy, and accelerate the clinical translation of next-generation nanovaccine platforms.
    • FullText(HTML)
  • loading
    • References(150)
  • [1]
    F. Bray, M. Laversanne, H. Sung, J. Ferlay, R.L. Siegel, I. Soerjomataram, A. Jemal, Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA. Cancer J. Clin. 74 (2024) 229-263. https://doi.org/10.3322/caac.21834.
    [2]
    A.C. Goncalves, E. Richiardone, J. Jorge, B. Polonia, C.P.R. Xavier, I.C. Salaroglio, C. Riganti, M.H. Vasconcelos, C. Corbet, A.B. Sarmento-Ribeiro, Impact of cancer metabolism on therapy resistance - Clinical implications, Drug Resist. Updat. 59 (2021) 100797. https://doi.org/10.1016/j.drup.2021.100797.
    [3]
    G. Morad, B.A. Helmink, P. Sharma, J.A. Wargo, Hallmarks of response, resistance, and toxicity to immune checkpoint blockade, Cell 184 (2021) 5309-5337. https://doi.org/10.1016/j.cell.2021.09.020.
    [4]
    M. Gupta, A. Wahi, P. Sharma, R. Nagpal, N. Raina, M. Kaurav, J. Bhattacharya, S.M. Rodrigues Oliveira, K.G. Dolma, A.K. Paul, M. de Lourdes Pereira, P. Wilairatana, M. Rahmatullah, V. Nissapatorn, Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects, Vaccines (Basel) 10 (2022). https://doi.org/10.3390/vaccines10122011.
    [5]
    M.C. Sellars, C.J. Wu, E.F. Fritsch, Cancer vaccines: Building a bridge over troubled waters, Cell 185 (2022) 2770-2788. https://doi.org/10.1016/j.cell.2022.06.035.
    [6]
    M. Hong, M. Liu, F. Zhu, D. Zhao, G. Liu, T. Han, C. Fei, W. Zeng, S. Chen, Q. Wu, B. Li, S. Wu, Y. Shang, H. Ma, S. Zhou, S. Xu, T. Jin, FcRn-guided antigen trafficking enhances cancer vaccine efficacy, Cancer Immunol Immunother 74 (2025) 54. https://doi.org/10.1007/s00262-024-03888-y.
    [7]
    Y. Zhang, J. Chen, L. Shi, F. Ma, Polymeric nanoparticle-based nanovaccines for cancer immunotherapy, Mater Horiz 10 (2023) 361-392. https://doi.org/10.1039/d2mh01358d.
    [8]
    M. Azharuddin, G.H. Zhu, A. Sengupta, J. Hinkula, N.K.H. Slater, H.K. Patra, Nano toolbox in immune modulation and nanovaccines, Trends Biotechnol 40 (2022) 1195-1212. https://doi.org/10.1016/j.tibtech.2022.03.011.
    [9]
    Y. Yi, M. Yu, W. Li, D. Zhu, L. Mei, M. Ou, Vaccine-like nanomedicine for cancer immunotherapy, J. Control. Release 355 (2023) 760-778. https://doi.org/10.1016/j.jconrel.2023.02.015.
    [10]
    K. Elumalai, S. Srinivasan, A. Shanmugam, Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment, Biomedical Technology 5 (2024) 109-122. https://doi.org/https://doi.org/10.1016/j.bmt.2023.09.001.
    [11]
    R. Malla, M. Srilatha, B. Farran, G.P. Nagaraju, mRNA vaccines and their delivery strategies: A journey from infectious diseases to cancer, Mol. Ther. 32 (2024) 13-31. https://doi.org/10.1016/j.ymthe.2023.10.024.
    [12]
    D. Weber, J. Ibn-Salem, P. Sorn, M. Suchan, C. Holtstrater, U. Lahrmann, I. Vogler, K. Schmoldt, F. Lang, B. Schrors, M. Lower, U. Sahin, Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens, Nat. Biotechnol. 40 (2022) 1276-1284. https://doi.org/10.1038/s41587-022-01247-9.
    [13]
    J. Lutz, R.K. Feist, T. Sonntag, E. Peguero-Sanchez, K. Wolter, R. Bick, J. Bauer, J.S. Walz, R. Heidenreich, Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma, Cancer Immunol. Immunother. 74 (2025) 329. https://doi.org/10.1007/s00262-025-04178-x.
    [14]
    A. Atmaca, J. Alt, D.V. Baz, R. Dziadziuszko, V. Moreno, V. Pose, O. Juan-Vidal, N. Munshi, J.L. Markman, V. Chen (2024): "1486 Preliminary results from LuCa-MERIT-1, a phase I trial evaluating BNT116, a fixed antigen mRNA vaccine, plus cemiplimab in advanced non-small cell lung cancer after progression on PD-1 inhibition," BMJ Specialist Journals.
    [15]
    Q.T. Wang, Y. Nie, S.N. Sun, T. Lin, R.J. Han, J. Jiang, Z. Li, J.Q. Li, Y.P. Xiao, Y.Y. Fan, X.H. Yuan, H. Zhang, B.B. Zhao, M. Zeng, S.Y. Li, H.X. Liao, J. Zhang, Y.W. He, Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients, Cancer Immunol. Immunother. 69 (2020) 1375-1387. https://doi.org/10.1007/s00262-020-02496-w.
    [16]
    J.A. Ligon, B. Stover, F. Weidert, A. Grippin, L. Fagman, J. Chardon-Robles, G. Jobin, C. Xie, D. Nguyen, N. Diodati (2023): "1363 Multilamellar mRNA lipid particle aggregate vaccines safely reprogram the tumor microenvironment and induce objective radiographic response in canines," BMJ Specialist Journals.
    [17]
    N.F. Saba, A. Sukari, F. Forget, A. Popovtzer, J.R. Perez, J. Park, M. Yang, M. Sato, M. Kuipers, R.J.I.J.o.R.O. Ito, Biology, Physics, HyperlynX: A phase 1b safety study of xevinapant, weekly cisplatin, and radiotherapy in patients with unresected locally advanced squamous cell carcinoma of the head and neck, 118 (2024) e21.
    [18]
    G.T. Wurz, C.J. Kao, M. Wolf, M.W. DeGregorio, Tecemotide: an antigen-specific cancer immunotherapy, Hum Vaccin Immunother 10 (2014) 3383-3393. https://doi.org/10.4161/hv.29836.
    [19]
    A. Veneziani, S. Lheureux, H. Alqaisi, G. Bhat, I. Colombo, E. Gonzalez, S. Newton, A. Msan, J. Quintos, J. Ramsahai, R.C. Grant, N.C. Dhani, L. Wang, V. Bowering, A.M. Oza, Pembrolizumab, maveropepimut-S, and low-dose cyclophosphamide in advanced epithelial ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial, J. Clin. Oncol. 40 (2022).
    [20]
    J.S. Weber, M.S. Carlino, A. Khattak, T. Meniawy, G. Ansstas, M.H. Taylor, K.B. Kim, M. McKean, G.V. Long, R.J. Sullivan, M. Faries, T.T. Tran, C.L. Cowey, A. Pecora, M. Shaheen, J. Segar, T. Medina, V. Atkinson, G.T. Gibney, J.J. Luke, S. Thomas, E.I. Buchbinder, J.A. Healy, M. Huang, M. Morrissey, I. Feldman, V. Sehgal, C. Robert-Tissot, P. Hou, L. Zhu, M. Brown, P. Aanur, R.S. Meehan, T. Zaks, Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study, Lancet 403 (2024) 632-644. https://doi.org/10.1016/s0140-6736(23)02268-7.
    [21]
    H. Bellberry, US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04526899 (2023), 2023 (accessed 2023).
    [22]
    M.E.E. Fernandez, J. Maurel, V. Morris, S. Kopetz, B. Galligan, S. Ali, E. Derhovanessian, K. Unsal-Kacmaz, L. Manning, H. Henn, T. Weisenburger, M. Tonigold, P. Zurek, M. Fierek-Ulbig, A. Cortini, M.P. Claveria, L. Preussner, F. Mueller, O. Tuereci, U. Sahin, Characterization of T cell responses induced by the individualized mRNA neoantigen vaccine autogene cevumeran in adjuvant stage II (high risk)/stage III colorectal cancer (CRC) patients (pts) from the biomarker cohort of the phase II BNT122-01 trial, Ann. Oncol. 35 (2024) S14-S15. https://doi.org/10.1016/j.annonc.2024.05.040.
    [23]
    C.C. Schimanski, S. Kasper, S. Hegewisch-Becker, J. Schroder, F. Overkamp, F. Kullmann, W.O. Bechstein, M. Vohringer, R. Ollinger, F. Lordick, V. Heinemann, M. Geissler, A. Schulz-Abelius, H. Bernhard, M.R. Schon, R. Greil, P. Galle, H. Lang, I. Schmidtmann, M. Moehler, Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC), Oncoimmunology 9 (2020) 1806680. https://doi.org/10.1080/2162402x.2020.1806680.
    [24]
    D.J. Martini, C.J.J.C.D. Wu, The Future of Personalized Cancer Vaccines, 15 (2025) 1315-1324.
    [25]
    X. Chen, M. Hu, T. Jin, K. Teng, Y. Han, Y. Zhou, K. Yang, Z. Zhang, J. Wang, Y.J.A.o.O. Cheng, 876P Evaluation of the safety and efficacy of ivonescimab in combination with ligufalimab as first-line (1L) treatment for PD-L1 positive recurrent/metastasis head and neck squamous cell carcinoma (R/M HNSCC), 35 (2024) S626-S627.
    [26]
    A.W. Silk, D. Davar, R. Ladwa, J. Lee, D. Schadendorf, C. Caglevic, F. Rey, P. Yanez, R.S. Meehan, T. Posadas (2024): "652 Adaptive phase 2/3 randomized study of neoadjuvant and adjuvant pembrolizumab with V940 (mRNA-4157) for resectable locally advanced cutaneous squamous cell carcinoma: INTerpath-007," BMJ Specialist Journals.
    [27]
    J.D. Spicer, S.M. Nair, A. Khattak, J.M. Lee, M. Brown, R.S. Meehan, N. Shariati, X. Deng, A. Samkari, J.E.J.C.R. Chaft, Abstract CT281: The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC), 84 (2024) CT281-CT281.
    [28]
    G. Richard, M.F. Princiotta, D. Bridon, W.D. Martin, G.D. Steinberg, A.S. De Groot, Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy, Expert Rev Vaccines 21 (2022) 173-184. https://doi.org/10.1080/14760584.2022.2012456.
    [29]
    W. Ning, S. Yan, Y. Song, H. Xu, J. Zhang, X. Wang, Virus-like particle: a nano-platform that delivers cancer antigens to elicit an anti-tumor immune response, Frontiers in immunology 15 (2024) 1504124. https://doi.org/10.3389/fimmu.2024.1504124.
    [30]
    P. Xu, F. Liang, Nanomaterial-Based Tumor Photothermal Immunotherapy, Int J Nanomedicine 15 (2020) 9159-9180. https://doi.org/10.2147/ijn.S249252.
    [31]
    D. Zhu, Y. Li, Z. Zhang, Z. Xue, Z. Hua, X. Luo, T. Zhao, C. Lu, Y. Liu, Recent advances of nanotechnology-based tumor vessel-targeting strategies, J Nanobiotechnology 19 (2021) 435. https://doi.org/10.1186/s12951-021-01190-y.
    [32]
    S. Talebian, T. Rodrigues, J. das Neves, B. Sarmento, R. Langer, J. Conde, Facts and Figures on Materials Science and Nanotechnology Progress and Investment, ACS Nano 15 (2021) 15940-15952. https://doi.org/10.1021/acsnano.1c03992.
    [33]
    K. Yuan, C. Deng, L. Tan, X. Wang, W. Yan, X. Dai, R. Du, Y. Zheng, H. Zhang, G. Wang, Structural and temporal dynamics analysis of zinc-based biomaterials: History, research hotspots and emerging trends, Bioact Mater 35 (2024) 306-329. https://doi.org/10.1016/j.bioactmat.2024.01.017.
    [34]
    N. Donthu, S. Kumar, D. Mukherjee, N. Pandey, W.M. Lim, How to conduct a bibliometric analysis: An overview and guidelines, Journal of Business Research 133 (2021) 285-296. https://doi.org/https://doi.org/10.1016/j.jbusres.2021.04.070.
    [35]
    Z. Pei, S. Chen, L. Ding, J. Liu, X. Cui, F. Li, F. Qiu, Current perspectives and trend of nanomedicine in cancer: A review and bibliometric analysis, J. Control. Release 352 (2022) 211-241. https://doi.org/10.1016/j.jconrel.2022.10.023.
    [36]
    C.M. Chen, CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature, Journal of the American Society for Information Science and Technology 57 (2006) 359-377. https://doi.org/10.1002/asi.20317.
    [37]
    J. Kleinberg, Bursty and hierarchical structure in streams, Data Mining and Knowledge Discovery 7 (2003) 373-397. https://doi.org/10.1023/a:1024940629314.
    [38]
    M. Rosvall, C.T. Bergstrom, Mapping change in large networks, PLoS One 5 (2010) e8694. https://doi.org/10.1371/journal.pone.0008694.
    [39]
    R. Kuai, L.J. Ochyl, K.S. Bahjat, A. Schwendeman, J.J. Moon, Designer vaccine nanodiscs for personalized cancer immunotherapy, Nat. Mater. 16 (2017) 489-+. https://doi.org/10.1038/nmat4822.
    [40]
    M. Saxena, S.H. van der Burg, C.J.M. Melief, N. Bhardwaj, Therapeutic cancer vaccines, Nat. Rev. Cancer 21 (2021) 360-378. https://doi.org/10.1038/s41568-021-00346-0.
    [41]
    Z. Hu, P.A. Ott, C.J. Wu, Towards personalized, tumour-specific, therapeutic vaccines for cancer, Nat. Rev. Immunol. 18 (2018) 168-182. https://doi.org/10.1038/nri.2017.131.
    [42]
    U. Sahin, O. Tureci, Personalized vaccines for cancer immunotherapy, Science 359 (2018) 1355-1360. https://doi.org/10.1126/science.aar7112.
    [43]
    P.A. Ott, Z. Hu, D.B. Keskin, S.A. Shukla, J. Sun, D.J. Bozym, W. Zhang, A. Luoma, A. Giobbie-Hurder, L. Peter, C. Chen, O. Olive, T.A. Carter, S. Li, D.J. Lieb, T. Eisenhaure, E. Gjini, J. Stevens, W.J. Lane, I. Javeri, K. Nellaiappan, A.M. Salazar, H. Daley, M. Seaman, E.I. Buchbinder, C.H. Yoon, M. Harden, N. Lennon, S. Gabriel, S.J. Rodig, D.H. Barouch, J.C. Aster, G. Getz, K. Wucherpfennig, D. Neuberg, J. Ritz, E.S. Lander, E.F. Fritsch, N. Hacohen, C.J. Wu, An immunogenic personal neoantigen vaccine for patients with melanoma, Nature 547 (2017) 217-+. https://doi.org/10.1038/nature22991.
    [44]
    M. Luo, L.Z. Samandi, Z. Wang, Z.J. Chen, J. Gao, Synthetic nanovaccines for immunotherapy, J. Control. Release 263 (2017) 200-210. https://doi.org/10.1016/j.jconrel.2017.03.033.
    [45]
    Q. Chen, L. Xu, C. Liang, C. Wang, R. Peng, Z. Liu, Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy, Nat. Commun. 7 (2016). https://doi.org/10.1038/ncomms13193.
    [46]
    U. Sahin, E. Derhovanessian, M. Miller, B.-P. Kloke, P. Simon, M. Loewer, V. Bukur, A.D. Tadmor, U. Luxemburger, B. Schroers, T. Omokoko, M. Vormehr, C. Albrecht, A. Paruzynski, A.N. Kuhn, J. Buck, S. Heesch, H. Katharina, F. Mueller, I. Ortseifer, I. Vogler, E. Godehardt, S. Attig, R. Rae, A. Breitkreuz, C. Tolliver, M. Suchan, G. Martic, A. Hohberger, P. Sorn, J. Diekmann, J. Ciesla, O. Waksmann, A.-K. Burck, M. Witt, M. Zillgen, A. Rothermel, B. Kasemann, D. Langer, S. Bolte, M. Diken, S. Kreiter, R. Nemecek, C. Gebhardt, S. Grabbe, C. Holler, J. Utikal, C. Huber, C. Loquai, O. Tuereci, Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer, Nature 547 (2017) 222-+. https://doi.org/10.1038/nature23003.
    [47]
    N. Pardi, M.J. Hogan, D. Weissman, Recent advances in mRNA vaccine technology, Curr. Opin. Immunol. 65 (2020) 14-20. https://doi.org/10.1016/j.coi.2020.01.008.
    [48]
    L.M. Kranz, M. Diken, H. Haas, S. Kreiter, C. Loquai, K.C. Reuter, M. Meng, D. Fritz, F. Vascotto, H. Hefesha, C. Grunwitz, M. Vormehr, Y. Huesemann, A. Selmi, A.N. Kuhn, J. Buck, E. Derhovanessian, R. Rae, S. Attig, J. Diekmann, R.A. Jabulowsky, S. Heesch, J. Hassel, P. Langguth, S. Grabbe, C. Huber, O. Tuereci, U. Sahin, Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy, Nature 534 (2016) 396-+. https://doi.org/10.1038/nature18300.
    [49]
    R. Kuai, L.J. Ochyl, K.S. Bahjat, A. Schwendeman, J.J. Moon, Designer vaccine nanodiscs for personalized cancer immunotherapy, Nat Mater 16 (2017) 489-496. https://doi.org/10.1038/nmat4822.
    [50]
    M. Luo, H. Wang, Z. Wang, H. Cai, Z. Lu, Y. Li, M. Du, G. Huang, C. Wang, X. Chen, M.R. Porembka, J. Lea, A.E. Frankel, Y.X. Fu, Z.J. Chen, J. Gao, A STING-activating nanovaccine for cancer immunotherapy, Nat. Nanotechnol. 12 (2017) 648-654. https://doi.org/10.1038/nnano.2017.52.
    [51]
    R.H. Fang, C.M. Hu, B.T. Luk, W. Gao, J.A. Copp, Y. Tai, D.E. O'Connor, L. Zhang, Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery, Nano Lett. 14 (2014) 2181-2188. https://doi.org/10.1021/nl500618u.
    [52]
    R. Yang, J. Xu, L. Xu, X. Sun, Q. Chen, Y. Zhao, R. Peng, Z. Liu, Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination, ACS Nano 12 (2018) 5121-5129. https://doi.org/10.1021/acsnano.7b09041.
    [53]
    P.H. Lizotte, A.M. Wen, M.R. Sheen, J. Fields, P. Rojanasopondist, N.F. Steinmetz, S. Fiering, In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer, Nat. Nanotechnol. 11 (2016) 295-303. https://doi.org/10.1038/nnano.2015.292.
    [54]
    G. Zhu, F. Zhang, Q. Ni, G. Niu, X. Chen, Efficient Nanovaccine Delivery in Cancer Immunotherapy, ACS Nano 11 (2017) 2387-2392. https://doi.org/10.1021/acsnano.7b00978.
    [55]
    J. Xu, J. Lv, Q. Zhuang, Z. Yang, Z. Cao, L. Xu, P. Pei, C. Wang, H. Wu, Z. Dong, Y. Chao, C. Wang, K. Yang, R. Peng, Y. Cheng, Z. Liu, A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy, Nat. Nanotechnol. 15 (2020) 1043-1052. https://doi.org/10.1038/s41565-020-00781-4.
    [56]
    L. Miao, L. Li, Y. Huang, D. Delcassian, J. Chahal, J. Han, Y. Shi, K. Sadtler, W. Gao, J. Lin, J.C. Doloff, R. Langer, D.G. Anderson, Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation, Nat. Biotechnol. 37 (2019) 1174-1185. https://doi.org/10.1038/s41587-019-0247-3.
    [57]
    M.A. Oberli, A.M. Reichmuth, J.R. Dorkin, M.J. Mitchell, O.S. Fenton, A. Jaklenec, D.G. Anderson, R. Langer, D. Blankschtein, Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy, Nano Lett. 17 (2017) 1326-1335. https://doi.org/10.1021/acs.nanolett.6b03329.
    [58]
    J.J. Moon, B. Huang, D.J. Irvine, Engineering nano- and microparticles to tune immunity, Adv. Mater. 24 (2012) 3724-3746. https://doi.org/10.1002/adma.201200446.
    [59]
    Z. Xu, S. Ramishetti, Y.C. Tseng, S. Guo, Y. Wang, L. Huang, Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis, J. Control. Release 172 (2013) 259-265. https://doi.org/10.1016/j.jconrel.2013.08.021.
    [60]
    G.N. Shi, C.N. Zhang, R. Xu, J.F. Niu, H.J. Song, X.Y. Zhang, W.W. Wang, Y.M. Wang, C. Li, X.Q. Wei, D.L. Kong, Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine, Biomaterials 113 (2017) 191-202. https://doi.org/10.1016/j.biomaterials.2016.10.047.
    [61]
    G.M. Lynn, C. Sedlik, F. Baharom, Y. Zhu, R.A. Ramirez-Valdez, V.L. Coble, K. Tobin, S.R. Nichols, Y. Itzkowitz, N. Zaidi, J.M. Gammon, N.J. Blobel, J. Denizeau, P. de la Rochere, B.J. Francica, B. Decker, M. Maciejewski, J. Cheung, H. Yamane, M.G. Smelkinson, J.R. Francica, R. Laga, J.D. Bernstock, L.W. Seymour, C.G. Drake, C.M. Jewell, O. Lantz, E. Piaggio, A.S. Ishizuka, R.A. Seder, Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens, Nat. Biotechnol. 38 (2020) 320-332. https://doi.org/10.1038/s41587-019-0390-x.
    [62]
    S. Hamdy, O. Molavi, Z. Ma, A. Haddadi, A. Alshamsan, Z. Gobti, S. Elhasi, J. Samuel, A. Lavasanifar, Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity, Vaccine 26 (2008) 5046-5057. https://doi.org/10.1016/j.vaccine.2008.07.035.
    [63]
    Z. Zhang, S. Tongchusak, Y. Mizukami, Y.J. Kang, T. Ioji, M. Touma, B. Reinhold, D.B. Keskin, E.L. Reinherz, T. Sasada, Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery, Biomaterials 32 (2011) 3666-3678. https://doi.org/10.1016/j.biomaterials.2011.01.067.
    [64]
    S. Liu, Q. Jiang, X. Zhao, R. Zhao, Y. Wang, Y. Wang, J. Liu, Y. Shang, S. Zhao, T. Wu, Y. Zhang, G. Nie, B. Ding, A DNA nanodevice-based vaccine for cancer immunotherapy, Nat. Mater. 20 (2021) 421-430. https://doi.org/10.1038/s41563-020-0793-6.
    [65]
    T. Fifis, A. Gamvrellis, B. Crimeen-Irwin, G.A. Pietersz, J. Li, P.L. Mottram, I.F. McKenzie, M. Plebanski, Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors, J. Immunol. 173 (2004) 3148-3154. https://doi.org/10.4049/jimmunol.173.5.3148.
    [66]
    I.H. Lee, H.K. Kwon, S. An, D. Kim, S. Kim, M.K. Yu, J.H. Lee, T.S. Lee, S.H. Im, S. Jon, Imageable antigen-presenting gold nanoparticle vaccines for effective cancer immunotherapy in vivo, Angew. Chem. Int. Ed. Engl. 51 (2012) 8800-8805. https://doi.org/10.1002/anie.201203193.
    [67]
    K. Niikura, T. Matsunaga, T. Suzuki, S. Kobayashi, H. Yamaguchi, Y. Orba, A. Kawaguchi, H. Hasegawa, K. Kajino, T. Ninomiya, K. Ijiro, H. Sawa, Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo, ACS Nano 7 (2013) 3926-3938. https://doi.org/10.1021/nn3057005.
    [68]
    J. Xiang, L. Xu, H. Gong, W. Zhu, C. Wang, J. Xu, L. Feng, L. Cheng, R. Peng, Z. Liu, Antigen-Loaded Upconversion Nanoparticles for Dendritic Cell Stimulation, Tracking, and Vaccination in Dendritic Cell-Based Immunotherapy, ACS Nano 9 (2015) 6401-6411. https://doi.org/10.1021/acsnano.5b02014.
    [69]
    H. Li, Y. Li, J. Jiao, H.M. Hu, Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response, Nat. Nanotechnol. 6 (2011) 645-650. https://doi.org/10.1038/nnano.2011.153.
    [70]
    Y. Guo, D. Wang, Q. Song, T. Wu, X. Zhuang, Y. Bao, M. Kong, Y. Qi, S. Tan, Z. Zhang, Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma, ACS Nano 9 (2015) 6918-6933. https://doi.org/10.1021/acsnano.5b01042.
    [71]
    R.A. Rosalia, L.J. Cruz, S. van Duikeren, A.T. Tromp, A.L. Silva, W. Jiskoot, T. de Gruijl, C. Lowik, J. Oostendorp, S.H. van der Burg, F. Ossendorp, CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses, Biomaterials 40 (2015) 88-97. https://doi.org/10.1016/j.biomaterials.2014.10.053.
    [72]
    Y. Fan, R. Kuai, Y. Xu, L.J. Ochyl, D.J. Irvine, J.J. Moon, Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy, Nano Lett. 17 (2017) 7387-7393. https://doi.org/10.1021/acs.nanolett.7b03218.
    [73]
    Y. Qian, H. Jin, S. Qiao, Y. Dai, C. Huang, L. Lu, Q. Luo, Z. Zhang, Targeting dendritic cells in lymph node with an antigen peptide-based nanovaccine for cancer immunotherapy, Biomaterials 98 (2016) 171-183. https://doi.org/10.1016/j.biomaterials.2016.05.008.
    [74]
    J. Conniot, A. Scomparin, C. Peres, E. Yeini, S. Pozzi, A.I. Matos, R. Kleiner, L.I.F. Moura, E. Zupancic, A.S. Viana, H. Doron, P.M.P. Gois, N. Erez, S. Jung, R. Satchi-Fainaro, H.F. Florindo, Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators, Nat. Nanotechnol. 14 (2019) 891-901. https://doi.org/10.1038/s41565-019-0512-0.
    [75]
    Y. Xia, J. Wu, W. Wei, Y. Du, T. Wan, X. Ma, W. An, A. Guo, C. Miao, H. Yue, S. Li, X. Cao, Z. Su, G. Ma, Exploiting the pliability and lateral mobility of Pickering emulsion for enhanced vaccination, Nat. Mater. 17 (2018) 187-194. https://doi.org/10.1038/nmat5057.
    [76]
    Z. Xu, Y. Wang, L. Zhang, L. Huang, Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment, ACS Nano 8 (2014) 3636-3645. https://doi.org/10.1021/nn500216y.
    [77]
    S.Y. Kim, Y.W. Noh, T.H. Kang, J.E. Kim, S. Kim, S.H. Um, D.B. Oh, Y.M. Park, Y.T. Lim, Synthetic vaccine nanoparticles target to lymph node triggering enhanced innate and adaptive antitumor immunity, Biomaterials 130 (2017) 56-66. https://doi.org/10.1016/j.biomaterials.2017.03.034.
    [78]
    N. Gong, Y. Zhang, X. Teng, Y. Wang, S. Huo, G. Qing, Q. Ni, X. Li, J. Wang, X. Ye, T. Zhang, S. Chen, Y. Wang, J. Yu, P.C. Wang, Y. Gan, J. Zhang, M.J. Mitchell, J. Li, X.J. Liang, Proton-driven transformable nanovaccine for cancer immunotherapy, Nat. Nanotechnol. 15 (2020) 1053-1064. https://doi.org/10.1038/s41565-020-00782-3.
    [79]
    I. Mellman, G. Coukos, G. Dranoff, Cancer immunotherapy comes of age, Nature 480 (2011) 480-489. https://doi.org/10.1038/nature10673.
    [80]
    K. Palucka, J. Banchereau, Cancer immunotherapy via dendritic cells, Nat. Rev. Cancer 12 (2012) 265-277. https://doi.org/10.1038/nrc3258.
    [81]
    D.J. Irvine, M.A. Swartz, G.L. Szeto, Engineering synthetic vaccines using cues from natural immunity, Nat. Mater. 12 (2013) 978-990. https://doi.org/10.1038/nmat3775.
    [82]
    K. Palucka, J. Banchereau, Dendritic-cell-based therapeutic cancer vaccines, Immunity 39 (2013) 38-48. https://doi.org/10.1016/j.immuni.2013.07.004.
    [83]
    D.J. Irvine, M.C. Hanson, K. Rakhra, T. Tokatlian, Synthetic Nanoparticles for Vaccines and Immunotherapy, Chem. Rev. 115 (2015) 11109-11146. https://doi.org/10.1021/acs.chemrev.5b00109.
    [84]
    H. Liu, K.D. Moynihan, Y. Zheng, G.L. Szeto, A.V. Li, B. Huang, D.S. Van Egeren, C. Park, D.J. Irvine, Structure-based programming of lymph-node targeting in molecular vaccines, Nature 507 (2014) 519-522. https://doi.org/10.1038/nature12978.
    [85]
    K. Shao, S. Singha, X. Clemente-Casares, S. Tsai, Y. Yang, P. Santamaria, Nanoparticle-based immunotherapy for cancer, ACS Nano 9 (2015) 16-30. https://doi.org/10.1021/nn5062029.
    [86]
    L.M. Kranz, M. Diken, H. Haas, S. Kreiter, C. Loquai, K.C. Reuter, M. Meng, D. Fritz, F. Vascotto, H. Hefesha, C. Grunwitz, M. Vormehr, Y. Husemann, A. Selmi, A.N. Kuhn, J. Buck, E. Derhovanessian, R. Rae, S. Attig, J. Diekmann, R.A. Jabulowsky, S. Heesch, J. Hassel, P. Langguth, S. Grabbe, C. Huber, O. Tureci, U. Sahin, Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy, Nature 534 (2016) 396-401. https://doi.org/10.1038/nature18300.
    [87]
    S.H. van der Burg, R. Arens, F. Ossendorp, T. van Hall, C.J. Melief, Vaccines for established cancer: overcoming the challenges posed by immune evasion, Nat. Rev. Cancer 16 (2016) 219-233. https://doi.org/10.1038/nrc.2016.16.
    [88]
    T.N. Schumacher, R.D. Schreiber, Neoantigens in cancer immunotherapy, Science 348 (2015) 69-74. https://doi.org/10.1126/science.aaa4971.
    [89]
    G.M. Lynn, R. Laga, P.A. Darrah, A.S. Ishizuka, A.J. Balaci, A.E. Dulcey, M. Pechar, R. Pola, M.Y. Gerner, A. Yamamoto, C.R. Buechler, K.M. Quinn, M.G. Smelkinson, O. Vanek, R. Cawood, T. Hills, O. Vasalatiy, K. Kastenmuller, J.R. Francica, L. Stutts, J.K. Tom, K.A. Ryu, A.P. Esser-Kahn, T. Etrych, K.D. Fisher, L.W. Seymour, R.A. Seder, In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity, Nat. Biotechnol. 33 (2015) 1201-1210. https://doi.org/10.1038/nbt.3371.
    [90]
    Q. Chen, L. Xu, C. Liang, C. Wang, R. Peng, Z. Liu, Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy, Nat. Commun. 7 (2016) 13193. https://doi.org/10.1038/ncomms13193.
    [91]
    U. Sahin, E. Derhovanessian, M. Miller, B.P. Kloke, P. Simon, M. Lower, V. Bukur, A.D. Tadmor, U. Luxemburger, B. Schrors, T. Omokoko, M. Vormehr, C. Albrecht, A. Paruzynski, A.N. Kuhn, J. Buck, S. Heesch, K.H. Schreeb, F. Muller, I. Ortseifer, I. Vogler, E. Godehardt, S. Attig, R. Rae, A. Breitkreuz, C. Tolliver, M. Suchan, G. Martic, A. Hohberger, P. Sorn, J. Diekmann, J. Ciesla, O. Waksmann, A.K. Bruck, M. Witt, M. Zillgen, A. Rothermel, B. Kasemann, D. Langer, S. Bolte, M. Diken, S. Kreiter, R. Nemecek, C. Gebhardt, S. Grabbe, C. Holler, J. Utikal, C. Huber, C. Loquai, O. Tureci, Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer, Nature 547 (2017) 222-226. https://doi.org/10.1038/nature23003.
    [92]
    A.W. Li, M.C. Sobral, S. Badrinath, Y. Choi, A. Graveline, A.G. Stafford, J.C. Weaver, M.O. Dellacherie, T.Y. Shih, O.A. Ali, J. Kim, K.W. Wucherpfennig, D.J. Mooney, A facile approach to enhance antigen response for personalized cancer vaccination, Nat. Mater. 17 (2018) 528-534. https://doi.org/10.1038/s41563-018-0028-2.
    [93]
    Y. Min, K.C. Roche, S. Tian, M.J. Eblan, K.P. McKinnon, J.M. Caster, S. Chai, L.E. Herring, L. Zhang, T. Zhang, J.M. DeSimone, J.E. Tepper, B.G. Vincent, J.S. Serody, A.Z. Wang, Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy, Nat. Nanotechnol. 12 (2017) 877-882. https://doi.org/10.1038/nnano.2017.113.
    [94]
    P.A. Ott, Z. Hu, D.B. Keskin, S.A. Shukla, J. Sun, D.J. Bozym, W. Zhang, A. Luoma, A. Giobbie-Hurder, L. Peter, C. Chen, O. Olive, T.A. Carter, S. Li, D.J. Lieb, T. Eisenhaure, E. Gjini, J. Stevens, W.J. Lane, I. Javeri, K. Nellaiappan, A.M. Salazar, H. Daley, M. Seaman, E.I. Buchbinder, C.H. Yoon, M. Harden, N. Lennon, S. Gabriel, S.J. Rodig, D.H. Barouch, J.C. Aster, G. Getz, K. Wucherpfennig, D. Neuberg, J. Ritz, E.S. Lander, E.F. Fritsch, N. Hacohen, C.J. Wu, An immunogenic personal neoantigen vaccine for patients with melanoma, Nature 547 (2017) 217-221. https://doi.org/10.1038/nature22991.
    [95]
    Z. Hu, P.A. Ott, C.J. Wu, Towards personalized, tumour-specific, therapeutic vaccines for cancer, Nat. Rev. Immunol. 18 (2018) 168-182. https://doi.org/10.1038/nri.2017.131.
    [96]
    N. Pardi, M.J. Hogan, F.W. Porter, D. Weissman, mRNA vaccines - a new era in vaccinology, Nat. Rev. Drug Discov. 17 (2018) 261-279. https://doi.org/10.1038/nrd.2017.243.
    [97]
    X. Hou, T. Zaks, R. Langer, Y. Dong, Lipid nanoparticles for mRNA delivery, Nat Rev Mater 6 (2021) 1078-1094. https://doi.org/10.1038/s41578-021-00358-0.
    [98]
    L.R. Baden, H.M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S.A. Spector, N. Rouphael, C.B. Creech, J. McGettigan, S. Khetan, N. Segall, J. Solis, A. Brosz, C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M. Marovich, J. Mascola, L. Polakowski, J. Ledgerwood, B.S. Graham, H. Bennett, R. Pajon, C. Knightly, B. Leav, W. Deng, H. Zhou, S. Han, M. Ivarsson, J. Miller, T. Zaks, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine, N. Engl. J. Med. 384 (2021) 403-416. https://doi.org/10.1056/NEJMoa2035389.
    [99]
    M. Saxena, S.H. van der Burg, C.J.M. Melief, N. Bhardwaj, Therapeutic cancer vaccines, Nat. Rev. Cancer 21 (2021) 360-378. https://doi.org/10.1038/s41568-021-00346-0.
    [100]
    M.J. Lin, J. Svensson-Arvelund, G.S. Lubitz, A. Marabelle, I. Melero, B.D. Brown, J.D. Brody, Cancer vaccines: the next immunotherapy frontier, Nat Cancer 3 (2022) 911-926. https://doi.org/10.1038/s43018-022-00418-6.
    [101]
    F.P. Polack, S.J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J.L. Perez, G. Perez Marc, E.D. Moreira, C. Zerbini, R. Bailey, K.A. Swanson, S. Roychoudhury, K. Koury, P. Li, W.V. Kalina, D. Cooper, R.W. Frenck, Jr., L.L. Hammitt, O. Tureci, H. Nell, A. Schaefer, S. Unal, D.B. Tresnan, S. Mather, P.R. Dormitzer, U. Sahin, K.U. Jansen, W.C. Gruber, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, N. Engl. J. Med. 383 (2020) 2603-2615. https://doi.org/10.1056/NEJMoa2034577.
    [102]
    Q. Cheng, T. Wei, L. Farbiak, L.T. Johnson, S.A. Dilliard, D.J. Siegwart, Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing, Nat. Nanotechnol. 15 (2020) 313-320. https://doi.org/10.1038/s41565-020-0669-6.
    [103]
    A. Akinc, M.A. Maier, M. Manoharan, K. Fitzgerald, M. Jayaraman, S. Barros, S. Ansell, X. Du, M.J. Hope, T.D. Madden, B.L. Mui, S.C. Semple, Y.K. Tam, M. Ciufolini, D. Witzigmann, J.A. Kulkarni, R. van der Meel, P.R. Cullis, The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs, Nat. Nanotechnol. 14 (2019) 1084-1087. https://doi.org/10.1038/s41565-019-0591-y.
    [104]
    X. Sun, Y. Zhang, J. Li, K.S. Park, K. Han, X. Zhou, Y. Xu, J. Nam, J. Xu, X. Shi, L. Wei, Y.L. Lei, J.J. Moon, Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy, Nat. Nanotechnol. 16 (2021) 1260-1270. https://doi.org/10.1038/s41565-021-00962-9.
    [105]
    S.A. Dilliard, Q. Cheng, D.J. Siegwart, On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles, Proc. Natl. Acad. Sci. U. S. A. 118 (2021). https://doi.org/10.1073/pnas.2109256118.
    [106]
    U. Sahin, P. Oehm, E. Derhovanessian, R.A. Jabulowsky, M. Vormehr, M. Gold, D. Maurus, D. Schwarck-Kokarakis, A.N. Kuhn, T. Omokoko, L.M. Kranz, M. Diken, S. Kreiter, H. Haas, S. Attig, R. Rae, K. Cuk, A. Kemmer-Bruck, A. Breitkreuz, C. Tolliver, J. Caspar, J. Quinkhardt, L. Hebich, M. Stein, A. Hohberger, I. Vogler, I. Liebig, S. Renken, J. Sikorski, M. Leierer, V. Muller, H. Mitzel-Rink, M. Miederer, C. Huber, S. Grabbe, J. Utikal, A. Pinter, R. Kaufmann, J.C. Hassel, C. Loquai, O. Tureci, An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma, Nature 585 (2020) 107-112. https://doi.org/10.1038/s41586-020-2537-9.
    [107]
    C. Liu, X. Liu, X. Xiang, X. Pang, S. Chen, Y. Zhang, E. Ren, L. Zhang, X. Liu, P. Lv, X. Wang, W. Luo, N. Xia, X. Chen, G. Liu, A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy, Nat. Nanotechnol. 17 (2022) 531-540. https://doi.org/10.1038/s41565-022-01098-0.
    [108]
    M. Qiu, Y. Tang, J. Chen, R. Muriph, Z. Ye, C. Huang, J. Evans, E.P. Henske, Q. Xu, Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis, Proc. Natl. Acad. Sci. U. S. A. 119 (2022). https://doi.org/10.1073/pnas.2116271119.
    [109]
    K. Cheng, R. Zhao, Y. Li, Y. Qi, Y. Wang, Y. Zhang, H. Qin, Y. Qin, L. Chen, C. Li, J. Liang, Y. Li, J. Xu, X. Han, G.J. Anderson, J. Shi, L. Ren, X. Zhao, G. Nie, Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology, Nat. Commun. 12 (2021) 2041. https://doi.org/10.1038/s41467-021-22308-8.
    [110]
    M.A. Islam, J. Rice, E. Reesor, H. Zope, W. Tao, M. Lim, J. Ding, Y. Chen, D. Aduluso, B.R. Zetter, O.C. Farokhzad, J. Shi, Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice, Biomaterials 266 (2021) 120431. https://doi.org/10.1016/j.biomaterials.2020.120431.
    [111]
    J. Chen, Z. Ye, C. Huang, M. Qiu, D. Song, Y. Li, Q. Xu, Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response, Proc. Natl. Acad. Sci. U. S. A. 119 (2022) e2207841119. https://doi.org/10.1073/pnas.2207841119.
    [112]
    S. Liu, Q. Cheng, T. Wei, X. Yu, L.T. Johnson, L. Farbiak, D.J. Siegwart, Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing, Nat. Mater. 20 (2021) 701-710. https://doi.org/10.1038/s41563-020-00886-0.
    [113]
    Z. Hu, D.E. Leet, R.L. Allesoee, G. Oliveira, S. Li, A.M. Luoma, J. Liu, J. Forman, T. Huang, J.B. Iorgulescu, R. Holden, S. Sarkizova, S.H. Gohil, R.A. Redd, J. Sun, L. Elagina, A. Giobbie-Hurder, W. Zhang, L. Peter, Z. Ciantra, S. Rodig, O. Olive, K. Shetty, J. Pyrdol, M. Uduman, P.C. Lee, P. Bachireddy, E.I. Buchbinder, C.H. Yoon, D. Neuberg, B.L. Pentelute, N. Hacohen, K.J. Livak, S.A. Shukla, L.R. Olsen, D.H. Barouch, K.W. Wucherpfennig, E.F. Fritsch, D.B. Keskin, C.J. Wu, P.A. Ott, Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma, Nat. Med. 27 (2021) 515-525. https://doi.org/10.1038/s41591-020-01206-4.
    [114]
    S. Tahtinen, A.J. Tong, P. Himmels, J. Oh, A. Paler-Martinez, L. Kim, S. Wichner, Y. Oei, M.J. McCarron, E.C. Freund, Z.A. Amir, C.C. de la Cruz, B. Haley, C. Blanchette, J.M. Schartner, W. Ye, M. Yadav, U. Sahin, L. Delamarre, I. Mellman, IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines, Nat. Immunol. 23 (2022) 532-542. https://doi.org/10.1038/s41590-022-01160-y.
    [115]
    H. Zhang, X. You, X. Wang, L. Cui, Z. Wang, F. Xu, M. Li, Z. Yang, J. Liu, P. Huang, Y. Kang, J. Wu, X. Xia, Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling, Proc. Natl. Acad. Sci. U. S. A. 118 (2021). https://doi.org/10.1073/pnas.2005191118.
    [116]
    W. Wang, C. Zou, X. Liu, L. He, Z. Cao, M. Zhu, Y. Wu, X. Liu, J. Ma, Y. Wang, Y. Zhang, K. Zhang, S. Wang, W. Zhang, W. Liu, W. Lin, Y. Zhang, Q. Guo, M. Li, J. Gu, Biomimetic Dendritic Cell-Based Nanovaccines for Reprogramming the Immune Microenvironment to Boost Tumor Immunotherapy, ACS Nano 18 (2024) 34063-34076. https://doi.org/10.1021/acsnano.4c09653.
    [117]
    N. Li, Y. Zhang, M. Han, T. Liu, J. Wu, Y. Xiong, Y. Fan, F. Ye, B. Jin, Y. Zhang, G. Sun, X. Sun, Z. Dong, Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines, Sci China Life Sci 67 (2024) 680-697. https://doi.org/10.1007/s11427-023-2465-x.
    [118]
    L. Lu, M. Yang, D. Deng, X. Shi, J.F. Lovell, H.J.C.C.R. Jin, Nanovaccines: Antigen selection, stabilization, adjuvantation, formulation, and evaluation, 541 (2025) 216806.
    [119]
    V. Trivedi, C. Yang, K. Klippel, O. Yegorov, C. von Roemeling, L. Hoang-Minh, G. Fenton, E. Ogando-Rivas, P. Castillo, G. Moore, K. Long-James, K. Dyson, B. Doonan, C. Flores, D.A. Mitchell, mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors, Genome Med. 16 (2024) 17. https://doi.org/10.1186/s13073-024-01281-z.
    [120]
    J.L.Y. Wu, Q. Ji, C. Blackadar, L.N.M. Nguyen, Z.P. Lin, Z. Sepahi, B.P. Stordy, A. Granda Farias, S. Sindhwani, W. Ngo, K. Chan, A. Habsid, J. Moffat, W.C.W. Chan, The pathways for nanoparticle transport across tumour endothelium, Nat. Nanotechnol. 20 (2025) 672-682. https://doi.org/10.1038/s41565-025-01877-5.
    [121]
    K. Poudel, T. Vithiananthan, J.O. Kim, H. Tsao, Recent progress in cancer vaccines and nanovaccines, Biomaterials 314 (2025) 122856. https://doi.org/10.1016/j.biomaterials.2024.122856.
    [122]
    M. Colaco, M.T. Cruz, L.P. Almeida, O. Borges, Mannose and Lactobionic Acid in Nasal Vaccination: Enhancing Antigen Delivery via C-Type Lectin Receptors, Pharmaceutics 16 (2024). https://doi.org/10.3390/pharmaceutics16101308.
    [123]
    J. Calmeiro, M. Carrascal, C. Gomes, A. Falcao, M.T. Cruz, B.M. Neves, Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy, Journal for immunotherapy of cancer 7 (2019) 238. https://doi.org/10.1186/s40425-019-0716-8.
    [124]
    Y. Huang, L. Zou, J. Wang, Q. Jin, J. Ji, Stimuli-responsive nanoplatforms for antibacterial applications, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 14 (2022) e1775. https://doi.org/10.1002/wnan.1775.
    [125]
    X.-P. Li, D.-Y. Hou, J.-C. Wu, P. Zhang, Y.-Z. Wang, M.-Y. Lv, Y. Yi, W. Xu, Stimuli-Responsive Nanomaterials for Tumor Immunotherapy, ACS Biomaterials Science & Engineering 10 (2024) 5474-5495. https://doi.org/10.1021/acsbiomaterials.4c00388.
    [126]
    S. Wang, Y. Hou, New Types of Magnetic Nanoparticles for Stimuli-Responsive Theranostic Nanoplatforms, Adv Sci (Weinh) 11 (2024) e2305459. https://doi.org/10.1002/advs.202305459.
    [127]
    A.R. Narciso, F. Iovino, S. Thorsdottir, P. Mellroth, M. Codemo, C. Spoerry, F. Righetti, S. Muschiol, S. Normark, P. Nannapaneni, B. Henriques-Normark, Membrane particles evoke a serotype-independent cross-protection against pneumococcal infection that is dependent on the conserved lipoproteins MalX and PrsA, Proc. Natl. Acad. Sci. U. S. A. 119 (2022) e2122386119. https://doi.org/10.1073/pnas.2122386119.
    [128]
    H. Ishikawa, Z. Ma, G.N. Barber, STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity, Nature 461 (2009) 788-792. https://doi.org/10.1038/nature08476.
    [129]
    Q. Li, H. Zeng, T. Liu, P. Wang, R. Zhang, B. Zhao, T. Feng, Y. Yang, J. Wu, Y. Zheng, B. Zhou, Y. Shu, H. Xu, L. Yang, Z. Ding, A dendritic cell vaccine for both vaccination and neoantigen-reactive T cell preparation for cancer immunotherapy in mice, Nat. Commun. 15 (2024) 10419. https://doi.org/10.1038/s41467-024-54650-y.
    [130]
    D.G. Fatouros, D.A. Lamprou, A.J. Urquhart, S.N. Yannopoulos, I.S. Vizirianakis, S. Zhang, S. Koutsopoulos, Lipid-like self-assembling peptide nanovesicles for drug delivery, ACS Appl Mater Interfaces 6 (2014) 8184-8189. https://doi.org/10.1021/am501673x.
    [131]
    D. Yin, Y. Zhong, S. Ling, S. Lu, X. Wang, Z. Jiang, J. Wang, Y. Dai, X. Tian, Q. Huang, X. Wang, J. Chen, Z. Li, Y. Li, Z. Xu, H. Jiang, Y. Wu, Y. Shi, Q. Wang, J. Xu, W. Hong, H. Xue, H. Yang, Y. Zhang, L. Da, Z.G. Han, S.C. Tao, R. Dong, T. Ying, J. Hong, Y. Cai, Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers, Nat Biomed Eng 9 (2025) 185-200. https://doi.org/10.1038/s41551-024-01208-4.
    [132]
    S. Xu, K. Yang, R. Li, L. Zhang, mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection, Int. J. Mol. Sci. 21 (2020). https://doi.org/10.3390/ijms21186582.
    [133]
    I. Abubakar, A. Plasencia, T. Barnighausen, G. Froeschl, M. Burton, F. Cobelens, Horizon Europe: towards a European agenda for global health research and innovation, Lancet 393 (2019) 1272-1273. https://doi.org/10.1016/s0140-6736(19)30287-9.
    [134]
    A. Alford, B. Tucker, V. Kozlovskaya, J. Chen, N. Gupta, R. Caviedes, J. Gearhart, D. Graves, E. Kharlampieva, Encapsulation and Ultrasound-Triggered Release of G-Quadruplex DNA in Multilayer Hydrogel Microcapsules, Polymers (Basel) 10 (2018). https://doi.org/10.3390/polym10121342.
    [135]
    S.R. Falsafi, H. Rostamabadi, K. Samborska, S. Mirarab, A. Rashidinejhad, S.M. Jafari, Protein-polysaccharide interactions for the fabrication of bioactive-loaded nanocarriers: Chemical conjugates and physical complexes, Pharmacol. Res. 178 (2022) 106164. https://doi.org/10.1016/j.phrs.2022.106164.
    [136]
    D.A. Salmon, W.A. Orenstein, S.A. Plotkin, R.T. Chen, Funding Postauthorization Vaccine-Safety Science, N. Engl. J. Med. 391 (2024) 102-105. https://doi.org/10.1056/NEJMp2402379.
    [137]
    M.S. Avumegah, G. Mattiuzzo, A. Sarnefalt, M. Page, K. Makar, J. Lathey, J. Kim, S.A. Yimer, D. Craig, I. Knezevic, V. Bernasconi, P.A. Kristiansen, I. Kromann, Availability and use of Standards in vaccine development, NPJ Vaccines 8 (2023) 95. https://doi.org/10.1038/s41541-023-00692-0.
    [138]
    A. Hasanzadeh, M.R. Hamblin, J. Kiani, H. Noori, J.M. Hardie, M. Karimi, H. Shafiee, Could artificial intelligence revolutionize the development of nanovectors for gene therapy and mRNA vaccines?, Nano Today 47 (2022). https://doi.org/10.1016/j.nantod.2022.101665.
    [139]
    Y. Xu, S. Ma, H. Cui, J. Chen, S. Xu, F. Gong, A. Golubovic, M. Zhou, K.C. Wang, A. Varley, R.X.Z. Lu, B. Wang, B. Li, AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery, Nat. Commun. 15 (2024) 6305. https://doi.org/10.1038/s41467-024-50619-z.
    [140]
    S. Li, S. Noroozizadeh, S. Moayedpour, L. Kogler-Anele, Z. Xue, D. Zheng, F.U. Montoya, V. Agarwal, Z. Bar-Joseph, S. Jager, mRNA-LM: full-length integrated SLM for mRNA analysis, Nucleic Acids Res. 53 (2025). https://doi.org/10.1093/nar/gkaf044.
    [141]
    X.M. Shao, R. Bhattacharya, J. Huang, I.K.A. Sivakumar, C. Tokheim, L. Zheng, D. Hirsch, B. Kaminow, A. Omdahl, M. Bonsack, A.B. Riemer, V.E. Velculescu, V. Anagnostou, K.A. Pagel, R. Karchin, High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets, Cancer Immunol Res 8 (2020) 396-408. https://doi.org/10.1158/2326-6066.Cir-19-0464.
    [142]
    A. Kumar, S. Dixit, K. Srinivasan, D. M, P. Vincent, Personalized cancer vaccine design using AI-powered technologies, Frontiers in immunology 15 (2024) 1357217. https://doi.org/10.3389/fimmu.2024.1357217.
    [143]
    S. He, J. Shang, Y. He, F. Wang, Enzyme-Free Dynamic DNA Reaction Networks for On-Demand Bioanalysis and Bioimaging, Acc. Chem. Res. (2024). https://doi.org/10.1021/acs.accounts.3c00676.
    [144]
    F. Yang, K. Shi, Y.P. Jia, Y. Hao, J.R. Peng, Z.Y. Qian, Advanced biomaterials for cancer immunotherapy, Acta Pharmacol. Sin. 41 (2020) 911-927. https://doi.org/10.1038/s41401-020-0372-z.
    [145]
    J. Whitley, C. Zwolinski, C. Denis, M. Maughan, L. Hayles, D. Clarke, M. Snare, H. Liao, S. Chiou, T. Marmura, H. Zoeller, B. Hudson, J. Peart, M. Johnson, A. Karlsson, Y. Wang, C. Nagle, C. Harris, D. Tonkin, S. Fraser, L. Capiz, C.L. Zeno, Y. Meli, D. Martik, D.A. Ozaki, A. Caparoni, J.E. Dickens, D. Weissman, K.O. Saunders, B.F. Haynes, G.D. Sempowski, T.N. Denny, M.R. Johnson, Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials, Transl. Res. 242 (2022) 38-55. https://doi.org/10.1016/j.trsl.2021.11.009.
    [146]
    D. Primorac, K. Vrdoljak, P. Brlek, E. Pavelic, V. Molnar, V. Matisic, I. Erceg Ivkosic, M. Parcina, Adaptive Immune Responses and Immunity to SARS-CoV-2, Front Immunol 13 (2022) 848582. https://doi.org/10.3389/fimmu.2022.848582.
    [147]
    V. Gyanani, R. Goswami, Key Design Features of Lipid Nanoparticles and Electrostatic Charge-Based Lipid Nanoparticle Targeting, Pharmaceutics 15 (2023). https://doi.org/10.3390/pharmaceutics15041184.
    [148]
    M.R. Zhang, L.L. Fang, Y. Guo, Q. Wang, Y.J. Li, H.F. Sun, S.Y. Xie, Y. Liang, Advancements in Stimulus-Responsive Co-Delivery Nanocarriers for Enhanced Cancer Immunotherapy, Int J Nanomedicine 19 (2024) 3387-3404. https://doi.org/10.2147/ijn.S454004.
    [149]
    S.S. Mohapatra, R.D. Frisina, S. Mohapatra, K.B. Sneed, E. Markoutsa, T. Wang, R. Dutta, R. Damnjanovic, M.H. Phan, D.J. Denmark, M.R. Biswal, A.R. McGill, R. Green, M. Howell, P. Ghosh, A. Gonzalez, N.T. Ahmed, B. Borresen, M. Farmer, M. Gaeta, K. Sharma, C. Bouchard, D. Gamboni, J. Martin, B. Tolve, M. Singh, J.W. Judy, C. Li, S. Santra, S. Daunert, E. Zeynaloo, R.M. Gelfand, S. Lenhert, E.S. McLamore, D. Xiang, V. Morgan, L.E. Friedersdorf, R. Lal, T.J. Webster, D.P. Hoogerheide, T.D. Nguyen, M.J. D'Souza, M. Culha, P.P.D. Kondiah, D.K. Martin, Advances in Translational Nanotechnology: Challenges and Opportunities, Appl Sci (Basel) 10 (2020). https://doi.org/10.3390/app10144881.
    [150]
    I. Hadj Hassine, Covid-19 vaccines and variants of concern: A review, Rev. Med. Virol. 32 (2022) e2313. https://doi.org/10.1002/rmv.2313.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (47) PDF downloads(0) Cited by()
    Proportional views
    Related

    Copyright © Journal of Pharmaceutical Analysis

    E-mail: jpasubmit@126.com;  jpaeditor@xjtu.edu.cn   Tel:+86-029-88960092

    Address: Western China Science and Technology Innovation Harbour, Xixian New Area, Xi’an, 712000, China

    Email alert RSS

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return